Danish educational materials
From November 15th 2016 the Danish Medicines Agency published Danish educational materials for human medicinal products approved via the national procedure, the mutual recognition procedure and the decentralised procedure.
From January 1st 2023 and forward – and not retroactively - the Danish Medicines Agency also publishes Danish educational materials for human medicinal products approved via the centralised procedure.
The marketing authorisation holder has the overall responsibility for the educational material and for ensuring that it complies with the conditions of the marketing authorisation. The marketing authorisation holder also has the overall responsibility for ensuring that the Danish Medicines Agency has the latest accepted written educational material available for publication.
Please refer to the section Dansk uddannelsesmateriale for the accepted and published Danish educational materials
| Name | Medicine Type | Strength | Active substance | Mft owner | Publish Date |
| Deferasirox "Glenmark" | filmovertrukne tabletter | 360 mg | Deferasirox | Glenmark Arzneimittel GmbH | 30/06/2022 |
| Deferasirox "Glenmark" | filmovertrukne tabletter | 90 mg | Deferasirox | Glenmark Arzneimittel GmbH | 30/06/2022 |
| Deferasirox "Glenmark" | filmovertrukne tabletter | 180 mg | Deferasirox | Glenmark Arzneimittel GmbH | 30/06/2022 |
| Deferasirox "Medical Valley" | filmovertrukne tabletter | 90 mg | Deferasirox | Medical Valley Invest AB | 05/08/2022 |
| Deferasirox "Medical Valley" | filmovertrukne tabletter | 180 mg | Deferasirox | Medical Valley Invest AB | 05/08/2022 |
| Deferasirox "Orifarm" | filmovertrukne tabletter | 90 mg | Deferasirox | Orifarm Generics A/S | 06/04/2022 |
| Deferasirox "Orifarm" | filmovertrukne tabletter | 360 mg | Deferasirox | Orifarm Generics A/S | 06/04/2022 |
| Deferasirox "Sandoz" | filmovertrukne tabletter | 90 mg | Deferasirox | Sandoz A/S | 06/04/2022 |
| Deferasirox "Sandoz" | filmovertrukne tabletter | 180 mg | Deferasirox | Sandoz A/S | 06/04/2022 |
| Deferasirox "Sandoz" | filmovertrukne tabletter | 360 mg | Deferasirox | Sandoz A/S | 06/04/2022 |
| Dehydrobenzperidol | injektionsvæske, opløsning | 2,5 mg/ml | Droperidol | Substipharm | 15/06/2017 |
| Delepsine | enterotabletter | 100 mg | NATRIUMVALPROAT | Orion Corporation | 11/07/2024 |
| Delepsine | enterotabletter | 300 mg | NATRIUMVALPROAT | Orion Corporation | 11/07/2024 |
| Delepsine | enterotabletter | 500 mg | NATRIUMVALPROAT | Orion Corporation | 11/07/2024 |
| Delepsine | oral opløsning | 60 mg/ml | NATRIUMVALPROAT | Orion Corporation | 11/07/2024 |
| Delepsine | orale dråber, opløsning | 200 mg/ml | NATRIUMVALPROAT | Orion Corporation | 11/07/2024 |
| Delepsine Retard | depottabletter | 300 mg | NATRIUMVALPROAT | Orion Corporation | 11/07/2024 |
| Delepsine Retard | depottabletter | 500 mg | NATRIUMVALPROAT | Orion Corporation | 11/07/2024 |
| Deprakine Retard | depottabletter | 300 mg | NATRIUMVALPROAT, Valproinsyre | Sanofi A/S | 11/07/2024 |
| Deprakine Retard | depottabletter | 500 mg | NATRIUMVALPROAT, Valproinsyre | Sanofi A/S | 11/07/2024 |
| Dexatin | tabletter | 5 mg | Dexamfetaminsulfat | Abboxia AB | 22/10/2024 |
| Dexatin | tabletter | 10 mg | Dexamfetaminsulfat | Abboxia AB | 22/10/2024 |
| Dexatin | tabletter | 20 mg | Dexamfetaminsulfat | Abboxia AB | 22/10/2024 |
| Dexfarm | tabletter | 5 mg | Dexamfetaminsulfat | Orifarm Healthcare A/S | 29/11/2024 |
| Dexfarm | tabletter | 10 mg | Dexamfetaminsulfat | Orifarm Healthcare A/S | 29/11/2024 |
| Dexfarm | tabletter | 20 mg | Dexamfetaminsulfat | Orifarm Healthcare A/S | 29/11/2024 |